Skip to main content
ACRV
NASDAQ Life Sciences

Acrivon Therapeutics Takes Full Control of ACR-368 Diagnostic Development In-House

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.53
Mkt Cap
$48.279M
52W Low
$1.05
52W High
$5.75
52W Position info
46% above low
Off High info
73% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ACRV sits 46% above its 52-week low of $1.05.

Summary

Acrivon Therapeutics is bringing the development and commercialization of its ACR-368 OncoSignature diagnostic test in-house, gaining full control over a critical component of its lead oncology program.


Key Events · Product Development and Regulatory · ACRV

  • Agreement Termination

    Acrivon Therapeutics and Akoya Biosciences mutually terminated their OncoSignature Companion Diagnostic Agreement, effective February 25, 2026.

  • In-House CLIA Lab

    The termination follows Acrivon's recent completion and certification of its own Clinical Laboratory Improvement Amendment (CLIA) certified laboratory.

  • Strategic Control

    Acrivon gains full development and commercialization rights to its proprietary ACR-368 OncoSignature test, enhancing control over biomarker identification and diagnostic development.

  • Operational Efficiency

    Bringing CLIA operations in-house is expected to improve capabilities and efficiencies, streamlining co-regulatory approvals and co-commercialization for current and future therapeutic agents.


Analysis · ACRV · Life Sciences

Acrivon Therapeutics has terminated its agreement with Akoya Biosciences, bringing the development and commercialization of its proprietary ACR-368 OncoSignature diagnostic test in-house. This strategic move, enabled by the company's newly certified CLIA laboratory, grants Acrivon full control over biomarker identification, companion diagnostic development, and regulatory processes for its lead oncology asset, ACR-368. This enhances operational efficiency and streamlines the path for potential co-regulatory approvals and co-commercialization, particularly important following recent positive Phase 2b clinical data for ACR-368.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACRV was trading at $1.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.3M. The 52-week trading range was $1.05 to $5.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACRV - Latest Insights

ACRV
Nov 16, 2026, 5:11 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.42 info
Change: -$0.0181 (-1%) info
Market Cap: $60.505M info
ACRV
Nov 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.42 info
Change: -$0.035 (-2%) info
Market Cap: $60.505M info
ACRV
Nov 16, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $1.42 info
Change: -$0.035 (-2%) info
Market Cap: $60.505M info
ACRV
Nov 10, 2026, 4:55 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.42 info
Change: -$0.185 (-12%) info
Market Cap: $60.505M info
ACRV
Nov 06, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.42 info
Change: -$0.185 (-12%) info
Market Cap: $60.505M info